skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Ibrutinib (Code C81934)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Ibrutinib

Definition: An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.

Display Name: Ibrutinib

Label: Ibrutinib

NCI Thesaurus Code: C81934 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2830052  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-
BTK Inhibitor PCI-32765

External Source Codes: 
CAS Registry Number 936563-96-1 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 638648
PDQ Open Trial Search ID 638648 (check for NCI PDQ open clinical trial info)
UMLS CUI C2830052

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C25H24N6O2
code C81934
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name BTK_Inhibitor_PCI-32765
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom